Related Experiment Videos
HBME-1 immunostaining in thyroid tumors especially in follicular neoplasm
Takahiro Mase1, Hiroomi Funahashi, Takashi Koshikawa
1Department of Surgery, Atsumi Hospital, Tahara, Aichi 441-3415, Japan.
Endocrine Journal
|June 14, 2003
Summary
The monoclonal antibody HBME-1 can help differentiate follicular adenoma from follicular carcinoma in thyroid neoplasms. Positive HBME-1 staining suggests malignancy and a higher risk of recurrence, aiding clinical diagnosis and patient follow-up.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Distinguishing between follicular adenoma and follicular carcinoma is challenging, even with permanent sections.
- Recurrence or metastasis can necessitate changing a diagnosis from benign follicular adenoma to malignancy.
- The monoclonal antibody HBME-1 shows reactivity in thyroid carcinomas.
Purpose of the Study:
- To investigate the diagnostic utility of the monoclonal antibody HBME-1 in follicular neoplasms.
- To assess HBME-1's effectiveness in differentiating benign and malignant follicular thyroid tumors.
Main Methods:
- Immunohistochemical staining for HBME-1 was performed on 205 thyroid tumors.
- The labeled streptavidin-biotin peroxidase method was employed.
- Cases were re-examined according to WHO Histological Classifications, 2nd Edition.
Main Results:
- HBME-1 was negative in most adenomatous goiter (87.2%) and follicular adenoma (72.6%) cases.
- HBME-1 was positive in a high percentage of follicular carcinoma (84.6%) and papillary carcinoma (97.2%) cases.
- Diagnostic accuracy for follicular neoplasms was 77.2%, with 84.6% sensitivity and 72.6% specificity.
Conclusions:
- Immunohistochemical staining with HBME-1 may aid in identifying follicular carcinoma with a high risk of recurrence.
- Benign adenoma cases with uncertain diagnoses require close clinical follow-up.
- HBME-1 positivity in cases initially diagnosed as follicular adenoma led to revised diagnoses of malignancy.